Hidradenitis Suppurativa

Jenkins, Toni; Isaac, Jahdonna; Edwards, Alicia; Okoye, Ginette A.

doi:10.1016/j.det.2023.02.001

Cited by 6 publications

(3 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several publications of ongoing clinical trials discuss the use of spesolimab (anti-IL-36 receptor) and JAK inhibitors, but so far there are too few reports to express a definitive opinion. [41][42][43][44][45][46][47][48][49][50][51][52][53][54][55][56][57][58] Larger Phase 3 studies will be needed to truly understand the efficacy and safety of these drugs for HS.…”

Section: Discussionmentioning

confidence: 99%

Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study

Martora,

Marasca,

Cacciapuoti

et al. 2024

CCID

View full text Add to dashboard Cite

Background:The treatment of hidradenitis suppurativa (HS) has always been a real challenge for dermatologists; to date, adalimumab the only biologic drug approved for HS is adalimumab, an anti-tumor necrosis factor (TNF)-α drug, the approval of this drug dates to 2015, data provided by real life show an effectiveness rate of about 60% percent. Recently (31 October 2023) FDA approves secukinumab for moderate-severe HS. The treatment and management of HS is very challenging as available treatments are very limited and show very variable outcomes. Methods: We conducted a prospective monocentric study designed to evaluate the efficacy and safety of secukinumab treatment in HS patients in a real-life setting. Results: The initial cohort of patients recruited included 21 HS patients including 12 females and 9 males. About 57.1% of patients achieved the primary endpoint and recorded significant decrease in all the severity assessment scales (IHS4, DLQI and VAS pain scale) at week 16 and 52, when HiSCR reached 71.4%. Conclusion:The results of our study highlight that treatment with secukinumab in patients with severe HS who failed adalimumab may be a safe and effective therapeutic weapon.

show abstract

Section: Discussionmentioning

confidence: 99%

Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study

Martora,

Marasca,

Cacciapuoti

et al. 2024

CCID

View full text Add to dashboard Cite

show abstract

“…Although the pathogenesis of HS is incompletely understood, the condition is thought to be triggered by follicular occlusion leading to subsequent follicular rupture and chronic, uncontrolled inflammation with eventual formation of draining and fibrotic tunnels. [1][2][3] Therefore, the hair follicle unit is thought to be a key contributor to HS disease pathogenesis.…”

Section: Introductionmentioning

confidence: 99%

“…Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder characterized by nodules, draining tunnels, and fibrotic scars primarily in intertriginous, hair‐bearing areas. Although the pathogenesis of HS is incompletely understood, the condition is thought to be triggered by follicular occlusion leading to subsequent follicular rupture and chronic, uncontrolled inflammation with eventual formation of draining and fibrotic tunnels 1–3 . Therefore, the hair follicle unit is thought to be a key contributor to HS disease pathogenesis.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of laser hair removal in hidradenitis suppurativa: A systematic review and meta‐analysis

Shipman,

Williams,

Suozzi

et al. 2024

Lasers Surg Med

View full text Add to dashboard Cite

ObjectivesHidradenitis suppurativa (HS) is a chronic inflammatory condition characterized by painful nodules, draining tunnels, and fibrotic scarring in intertriginous, hair‐bearing areas. The pathogenesis involves follicular occlusion and subsequent rupture, leading to uncontrolled inflammation. Treatment options for HS are limited and lack universal effectiveness. Laser hair removal (LHR) has been explored as a potential treatment; however, the efficacy and appropriate laser modalities remain unclear. This systematic review examined the efficacy and adverse effects of LHR in HS.MethodsA comprehensive literature search was conducted from inception to September 2023 in Ovid MEDLINE, Ovid Embase, and The Cochrane Library (Wiley) with predefined inclusion and exclusion criteria, and a meta‐analysis was conducted.ResultsTen studies were selected (n = 227 total patients) and included six randomized controlled trials, two nonrandomized experimental studies, and two case series. Various laser modalities, including long‐pulsed neodymium‐doped yttrium aluminum garnet (Nd:YAG) (n = 115), intense pulsed light (n = 18), Alexandrite (n = 54), intralesional 1064 nm diode (n = 20), and combined fractional CO2 and long‐pulsed Nd:YAG laser (n = 20), consistently demonstrated significant improvement in HS disease severity, irrespective of the disease scoring method used. Minimal adverse effects (primarily mild pain and erythema) were reported. A meta‐analysis of three studies utilizing long‐pulsed Nd:YAG laser demonstrated a standardized mean difference in disease severity of −1.68 (95% confidence interval: −2.99; −0.37), favoring treatment with LHR for HS.ConclusionsHair follicles are key in HS pathogenesis and all included studies showed a significant improvement in HS disease severity after LHR regardless of the laser device used, likely related to hair follicle unit destruction. HS is a complex and heterogenous condition, and multiple disease scoring methods complicate outcome comparisons across studies. However, LHR, utilizing various techniques, is an effective treatment option for HS with minimal adverse effects.

show abstract

Association between hidradenitis suppurativa and increased risk of venous thromboembolism: A multicenter retrospective cohort study

Garate,

Woolridge,

Wilkerson

et al. 2024

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Hidradenitis Suppurativa

Cited by 6 publications

References 50 publications

Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study

Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study

Efficacy of laser hair removal in hidradenitis suppurativa: A systematic review and meta‐analysis

Association between hidradenitis suppurativa and increased risk of venous thromboembolism: A multicenter retrospective cohort study

Contact Info

Product

Resources

About